Epcoritamab in B-cell malignancies: current status and prospects

Expert Opin Biol Ther. 2024 Jan-Feb;24(1-2):1-5. doi: 10.1080/14712598.2024.2310148. Epub 2024 Feb 11.

Authors

Stefano Molica¹, Marco Rossi^{2

3}, David Allsup^{1

4}

Affiliations

¹ Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull University NHS Trust, Hull, UK.
² Department Haematology, Azienda Ospedaliera-Universitaria "Renato Dulbecco", Catanzaro, Italy.
³ Università Magna Graecia, Catanzaro, Italy.
⁴ Centre of Biomedicine, Hull York Medical School, University of Hull, Hull, UK.

PMID: 38343083
DOI: 10.1080/14712598.2024.2310148

No abstract available

Keywords: Epcoritamab; chronic lymphocytic leukemia; diffuse large B-cell lymphoma; follicular lymphoma.

Publication types

Editorial

MeSH terms

Antineoplastic Agents* / therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Lymphoma, Follicular* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Non-Hodgkin* / drug therapy

Substances

Antineoplastic Agents